Rhythm Historical Income Statement
| RYTM Stock | USD 54.54 0.12 0.22% |
Historical analysis of Rhythm Pharmaceuticals income statement accounts such as Research Development of 163 M, Total Operating Expenses of 304.9 M, Total Other Income Expense Net of 265.5 K or Total Revenue of 93.5 M can show how well Rhythm Pharmaceuticals performed in making a profits. Evaluating Rhythm Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Rhythm Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Rhythm Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Rhythm Pharmaceuticals is a good buy for the upcoming year.
Rhythm |
About Rhythm Income Statement Analysis
Rhythm Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Rhythm Pharmaceuticals shareholders. The income statement also shows Rhythm investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Rhythm Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Rhythm Pharmaceuticals. It is also known as Rhythm Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Most accounts from Rhythm Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Rhythm Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.At this time, Rhythm Pharmaceuticals' Gross Profit is very stable compared to the past year. As of the 18th of January 2025, Cost Of Revenue is likely to grow to about 11.2 M, though Operating Income is likely to grow to (157.6 M).
| 2022 | 2023 | 2024 | 2025 (projected) | Reconciled Depreciation | 1.7M | 1.8M | 2.1M | 1.1M | Interest Income | 4.0M | 13.2M | 15.1M | 15.9M |
Rhythm Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Rhythm Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Rhythm Pharmaceuticals income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 690K | 1.2M | 1.4M | 1.8M | 2.0M | 2.1M | |
| Selling General Administrative | 46.1M | 68.5M | 92.0M | 111.5M | 128.2M | 134.6M | |
| Other Operating Expenses | 136.6M | 173.2M | 202.8M | 261.8M | 301.1M | 316.1M | |
| Operating Income | (136.6M) | (170.1M) | (179.2M) | (184.4M) | (165.9M) | (157.6M) | |
| Ebit | (136.6M) | (170.1M) | (175.9M) | (170.2M) | (153.2M) | (145.5M) | |
| Research Development | 90.5M | 104.1M | 108.6M | 135.0M | 155.2M | 163.0M | |
| Ebitda | (135.9M) | (168.9M) | (174.5M) | (168.5M) | (151.6M) | (144.0M) | |
| Total Operating Expenses | 136.6M | 172.6M | 200.7M | 252.5M | 290.4M | 304.9M | |
| Income Before Tax | (134.0M) | (69.6M) | (181.1M) | (184.1M) | (165.7M) | (157.4M) | |
| Total Other Income Expense Net | 2.6M | 100.4M | (2.0M) | 243K | 279.5K | 265.5K | |
| Net Income | (130.7M) | (68.0M) | (183.1M) | (184.7M) | (166.2M) | (157.9M) | |
| Total Revenue | 35K | 3.2M | 23.6M | 77.4M | 89.0M | 93.5M | |
| Gross Profit | (690K) | 2.6M | 21.5M | 68.1M | 78.3M | 82.3M | |
| Net Income From Continuing Ops | (134.0M) | (69.6M) | (181.1M) | (185.5M) | (167.0M) | (158.6M) | |
| Cost Of Revenue | 690K | 599K | 2.1M | 9.3M | 10.7M | 11.2M | |
| Net Income Applicable To Common Shares | (140.7M) | (134.0M) | (69.6M) | (181.1M) | (163.0M) | (154.9M) | |
| Income Tax Expense | (3.3M) | (1.6M) | 2.0M | 564K | 507.6K | 533.0K | |
| Net Interest Income | 2.6M | 447K | (1.2M) | 814K | 732.6K | 1.3M | |
| Interest Income | 2.6M | 447K | 4.0M | 13.2M | 15.1M | 15.9M | |
| Reconciled Depreciation | 690K | 1.2M | 1.7M | 1.8M | 2.1M | 1.1M | |
| Non Operating Income Net Other | 5.3M | 2.6M | 100.4M | 3.2M | 3.7M | 3.5M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share | Quarterly Revenue Growth 0.478 | Return On Assets | Return On Equity |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.